Pulmonary Involvement in Systemic Onset Juvenile Arthritis: Current Status of the Problem
https://doi.org/10.15690/vsp.v20i1.2234
Abstract
Systemic onset juvenile arthritis is the complex autoinflammatory disease with multigenic type of inheritance. It is characterized by significant systemic manifestations and unfavourable adverse events, among which macrophage activation syndrome and pulmonary involvement are playing crucial role. This article presents data on the frequency and features of the disease course, possible development predictors and clinical-radiological picture of pulmonary involvement in systemic onset juvenile arthritis. Possible factors (including hereditary) affecting the process of pulmonary involvement development and the role of genetically engineered biologic therapy are considered.
Keywords
systemic onset juvenile arthritis,
macrophage activation syndrome,
pulmonary involvement in children,
interstitial lung disease,
pulmonary alveolar proteinosis,
pulmonary hypertension
Supporting agencies: Not specified.
About the Authors
Maria I. Kaleda
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow.
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Not declared.
Irina P. Nikishina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow.
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Not declared.
Svetlana R. Rodionovskaya
Federal Clinical Research Centre of Children and Adolescents of Federal Medico-Biological Agency of Russia
Russian Federation
Moscow.
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Not declared.
Ekaterina V. Nikolaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow.
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Not declared.
References
1. De Benedetti F, Schneider R. Systemic Juvenile Idiopathic Arthritis In: Textbook of pediatric rheumatology. Petty R, Lindsley C, Laxer R, et al., eds. 7th ed. Philadelphia, PA: Elsevier, 2016. pp. 206-216.
2. Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol. 2015; 159(1):72-83. doi: 10.1016/j.clim.2015.04.018
3. Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46(2):190-197. doi: 10.3899/jrheum.180168
4. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289-298. doi: 10.1038/gene.2012.3
5. Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62(2): 599-608. doi: 10.1002/art.27218
6. Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669-679. doi: 10.1093/rheumatology/kev382
7. Nikishina IP, Kaleda MI. Current pharmacotherapy for systemic juvenile arthritis. Rheumatology Science and Practice. 2015;53(1):84-93. (In Russ). doi: 10.14412/1995-4484-2015-84-93
8. Kaleda MI, Nikishina IP. Totsilizumab in the treatment of children with a systemic variant of juvenile arthritis: an analysis of factors affecting the effectiveness of therapy in the long term. Voprosy Sovremennoi Pediatrii — Current Pediatrics. 2015;14(2):236-245. (In Russ). doi: 10.15690/vsp.v14i2.1292
9. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016; 12(5):259-268. doi: 10.1038/nrrheum.2015.179
10. Padeh S, Laxer RM, Silver MM, Silverman ED. Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum. 1991;34(12):1575-1579. doi: 10.1002/art.1780341216
11. Nolan PK, Daniels C, Long F, et al. Severe diffusion capacity reduction in a case of systemic onset juvenile rheumatoid arthritis with mild pulmonary hypertension [abstract]. Chest. 2005;128 (4 Suppl):435S. doi: 10.1378/chest.128.4_MeetingAbstracts.435S-a
12. Sato K, Takahashi H, Amano H, et al. Diffuse progressive pulmonary interstitial and intra-alveolar cholesterol granulomas in childhood. Eur Respir J. 1996;9(11):2419-2422. doi: 10.1183/09031936.96.09112419
13. Schultz R, Mattila J, Gappa M, Verronen P. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA). Pediatr Pulmonol. 2001;32(5):397-402. doi: 10.1002/ppul.1149
14. Boytsova EV, Ovsyannikov DU, Belyashova MA. Pediatric interstitial lung disease: children patients are not little adults. Pediatria n.a. G.N. Speransky. 2015; 94(4):171-176. (In Russ).
15. Schulert GS, Yasin S, Carey B, et al. Systemic Juvenile Idiopathic Arthritis — Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol. 2019;71(11):1943-1954. doi: 10.1002/art.41073
16. De Groot J, Vastert B, Giancane G, et al. Interstitial lung disease in systemic juvenile idiopathic arthritis patients in the Pharmachild registry. Pediatric Rheumatology. 2018;16(52):Abstract P004. doi: 10.1186/s12969-018-0265-6
17. Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65(5):745-752. doi: 10.1002/acr.21889
18. Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12): 1722-1731. doi: 10.1136/annrheumdis-2019-216040
19. Inaba H, Jenkins JJ, McCarville MB, et al. Pulmonary alveolar proteinosis in pediatric leukemia. Pediatr Blood Cancer. 2008; 51(1):66-70. doi: 10.1002/pbc.21442
20. Sullivan KD, Evans D, Pandey A, et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep. 2017;7(1):14818. doi: 10.1038/s41598-017-13858-3
21. Kostik MM, Isupova EA, Rumyantseva MV, et al. Interstitial lung disease in patients with juvenile arthritis with systemic onset: a description of a series of clinical cases with bibliographical review. Pediatria n.a. G.N. Speransky. 2020;99(2):125-136. (In Russ). doi: 10.24110/0031-403X-2020-99-2-125-136
22. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015; 46(4):976-987. doi: 10.1183/13993003.00150-2015
23. Davies R, Southwood T, Kearsley-Fleet L, et al. Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. Arch Dis Child. 2017;102(2):206-207. doi: 10.1136/archdis-child-2016-311571
24. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345-348. doi: 10.1016/j.cyto.2012.11.025
25. Put K, Avau A, Brisse E, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-у. Rheumatology (Oxford). 2015;54(8):1507-1517. doi: 10.1093/rheumatology/keu524
26. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151(5):1628-1631. doi: 10.1164/ajrccm.151.5.7735624
27. Weiss JE, Lee T, Rabinovich CE, et al. Life-threatening Pulmonary Hypertension (PH) and Alveolar Proteinosis (AP) in Systemic JIA (SJIA). Arthritis Rheum. 2008;58(9S):S257-S258.
28. Ong MS, Mullen MP, Austin ED, et al. Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension. Circ Res. 2017;121(4):341-353. doi: 10.1161/CIRCRESAHA.117.310804
29. Kitamura N, Ohkouchi S, Tazawa R, et al. Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution. ERJ Open Res. 2019;5(1):00190-02018. doi: 10.1183/23120541.00190-2018
30. Ishii H, Tazawa R, Kaneko C, et al. Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. Eur Respir J. 2011;37(2):465-468. doi: 10.1183/09031936.00092910
31. Huaux F, De Gussem V, Lebrun A, et al. New interplay between interstitial and alveolar macrophages explains pulmonary alveolar proteinosis (PAP) induced by indium tin oxide particles. Arch Toxicol. 2018;92(4):1349-1361. doi: 10.1007/s00204-018-2168-1
32. Dirksen U, Hattenhorst U, Schneider P, et al. Defective expression of granulocyte macrophage colony-stimulating factor/ interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failure. Blood. 1998;92(4):1097-1103.
33. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis [published correction appears in N Engl J Med. 2015 Feb 26;372(9):887]. N Engl J Med. 2012;367(25):2385-2395. doi: 10.1056/NEJMoa1112802
34. Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75(9):1654-1660. doi: 10.1136/annrheumdis-2015-207818
35. Schulert GS, Minoia F, Bohnsack J, et al. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2018;70(3):409-419. doi: 10.1002/acr.23277
36. Saper V, Mellins E, Kwong B. Drug reaction and high fatality lung disease in systemic onset juvenile idiopathic arthritis (sJIA). J Allergy Clin Immunol. 2020;145(Suppl 2):AB95. doi: 10.1016/j.jaci.2019.12.598
37. Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019;71(7):1163-1173. doi: 10.1002/art.40865
Review
For citations:
Kaleda M.I., Nikishina I.P., Rodionovskaya S.R., Nikolaeva E.V. Pulmonary Involvement in Systemic Onset Juvenile Arthritis: Current Status of the Problem. Current Pediatrics. 2021;20(1):31-37. (In Russ.) https://doi.org/10.15690/vsp.v20i1.2234
Views:
842
Email this article 
